NEW YORK, Dec 19 - Oxford GlycoSciences has extended a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS announced Tuesday.
The new agreement continues a joint research collaboration the two companies began in April 1998 for another two years.
Under the terms of the collaboration, Pfizer will have access to OGS’s CSF Proteome and Serum Proteome databases. This marks the first access agreement for the databases since OGS renegotiated its licensing agreement with Incyte earlier in the year to permit non-exclusive use of the databases.
Pfizer will provide further research funding to OGS and pay success-related milestone payments. Pfizer will also make a small equity investment in OGS and will pay for time in the OGS proteomics facility.
Further terms of the new agreement were not disclosed.
Stephen Parker, chief financial officer of OGS, said: “The first part of the deal with Pfizer was very successful in discovering proteins that are useful as biomarkers. The purpose of this part of the deal is to determine clinical usage of these as biomarkers. From there, we’ll be increasing the capability of the agreement in order to earn the milestones that will be covered in the deal.”
Parker said that OGS would be willing to license the CSF Proteome and Serum Proteome databases to other partners “as appropriate.”
“We firmly believe there is a business in databases,” Parker said.
OGS has entered into similar proteomics collaborations with Bayer on respiratory disease, Merck on Alzheimer’s disease, Medarex for human therapeutic antibodies, and Glaxo Wellcome for nine diseases, including osteoarthritis, rheumatoid arthritis, dislipidemia, liver fibrosis, epithelial carcinomas, acute migraines, hypertension, metabolic syndrome x, and unipolar depression.